{"id":4192,"date":"2022-03-03T12:18:12","date_gmt":"2022-03-03T11:18:12","guid":{"rendered":"https:\/\/www.mc-praha.cz\/mcp\/?p=4192"},"modified":"2022-03-03T12:20:10","modified_gmt":"2022-03-03T11:20:10","slug":"vla2001-valneva-vakcina-proti-covid-19-na-bazi-inaktivovaneho-viru","status":"publish","type":"post","link":"https:\/\/www.mc-praha.cz\/mcp\/vla2001-valneva-vakcina-proti-covid-19-na-bazi-inaktivovaneho-viru\/","title":{"rendered":"VLA2001 (Valneva) \u2013 vakc\u00edna proti COVID-19 na b\u00e1zi inaktivovan\u00e9ho viru"},"content":{"rendered":"

K\u00a0zaji\u0161t\u011bn\u00ed imunity proti onemocn\u011bn\u00ed COVID-19 se v\u00a0\u010cR aktu\u00e1ln\u011b pou\u017e\u00edv\u00e1 n\u011bkolik vakc\u00edn vyroben\u00fdch r\u016fzn\u00fdmi technologiemi. Dal\u0161\u00ed se z\u00e1jmem o\u010dek\u00e1vanou je vakc\u00edna VLA2001, kterou vyv\u00edjej\u00ed t\u00fdmy v\u011bdc\u016f <\/strong>biotechnologick\u00e9 spole\u010dnosti Valneva ve Francii a Rakousku. <\/strong>Jedn\u00e1 se o tradi\u010dn\u011b konstruovanou vakc\u00ednu na b\u00e1zi inaktivovan\u00e9ho viru. Evropsk\u00e1 agentura pro l\u00e9\u010div\u00e9 p\u0159\u00edpravky (EMA) zah\u00e1jila jej\u00ed pr\u016fb\u011b\u017en\u00fd p\u0159ezkum. Po jej\u00edm schv\u00e1len\u00ed by se o n\u00e1kupu t\u00e9to vakc\u00edny mohlo jednat i v\u00a0\u010cR, Evropsk\u00e1 komise ji\u017e objednala u v\u00fdrobce 60 milion\u016f d\u00e1vek. <\/strong><\/p>\n

Vakc\u00edna VLA2001 proti COVID-19 byla vyvinuta tradi\u010dn\u00edm zp\u016fsobem ze \u017eiv\u00e9ho viru (v\u00a0tomto p\u0159\u00edpad\u011b SARS-CoV-2), kter\u00fd je chemicky inaktivov\u00e1n (usmrcen, nem\u016f\u017ee tedy zp\u016fsobit infekci). Obsahuje tak\u00e9 koloidn\u00ed hydroxid hlinit\u00fd a oligonukleotid CpG 1018 jako adjuvans k pos\u00edlen\u00ed imunitn\u00ed odpov\u011bdi. Po pod\u00e1n\u00ed vakc\u00edny imunitn\u00ed syst\u00e9m inaktivovan\u00fd virus vyhodnot\u00ed jako cizorodou \u010d\u00e1stici a vytvo\u0159\u00ed si proti n\u011bmu protil\u00e1tky. Pokud se pozd\u011bji o\u010dkovan\u00e1 osoba dostane do kontaktu s \u017eiv\u00fdm virem SARS-CoV-2, imunitn\u00ed syst\u00e9m virus rozpozn\u00e1 a bude p\u0159ipraven se mu br\u00e1nit.<\/p>\n

Stejn\u00e1 v\u00fdrobn\u00ed technologie se dlouhodob\u011b pou\u017e\u00edv\u00e1 u \u0159ady jin\u00fdch vakc\u00edn (nap\u0159. proti ch\u0159ipce, ne\u0161tovic\u00edm \u010di obrn\u011b). Tak\u00e9 u vakc\u00edny Ixario, kterou vyvinula spole\u010dnost Valneva proti japonsk\u00e9 meningitid\u011b. Ta je pod\u00e1v\u00e1na u\u017e p\u0159es 10 let a pro\u0161la i 3let\u00fdmi post-klinick\u00fdmi zkou\u0161kami. Mimo EU bylo pro\u00a0boj proti SARS-CoV-2 u\u017e n\u011bkolik inaktivovan\u00fdch vakc\u00edn vytvo\u0159eno, nap\u0159\u00edklad \u010d\u00ednsk\u00e9 vakc\u00edny CoronaVac, Sinopharm BIBP a WIBP, indick\u00fd Covaxin \u010di rusk\u00fd CoviVac.<\/p>\n

Oproti aktu\u00e1ln\u011b u n\u00e1s pou\u017e\u00edvan\u00fdm protikovidov\u00fdm vakc\u00edn\u00e1m aktivuje VLA2001 bun\u011b\u010dnou imunitn\u00ed odpov\u011b\u010f nejen na tzv. spike protein na povrchu viru SARS-CoV-2, ale na cel\u00fd vir, tj. v\u010detn\u011b dal\u0161\u00edch d\u016fle\u017eit\u00fdch b\u00edlkovin uvnit\u0159 viru. Imunitn\u00ed odpov\u011b\u010f se tak o\u010dek\u00e1v\u00e1 komplexn\u011bj\u0161\u00ed. Tato vakc\u00edna by podle n\u011bkter\u00fdch odborn\u00edk\u016f proto mohla \u00fa\u010dinn\u011bji chr\u00e1nit p\u0159ed p\u0159\u00edpadn\u00fdmi dal\u0161\u00edmi mutacemi SARS-CoV-2 a mohla by b\u00fdt zaj\u00edmav\u00e1 tak\u00e9 p\u0159edpokl\u00e1danou minim\u00e1ln\u00ed incidenc\u00ed vedlej\u0161\u00edch \u00fa\u010dink\u016f. Nyn\u00ed fini\u0161uje f\u00e1ze III klinick\u00fdch zkou\u0161ek, nam\u00edsto rychlosti byla vyv\u00edjena s d\u016frazem na bezpe\u010dnost.<\/p>\n

Spole\u010dnost Valneva zah\u00e1jila v\u00a0souvislosti s\u00a0vakc\u00ednou VLA2001 dal\u0161\u00ed r\u016fzn\u011b c\u00edlen\u00e9 klinick\u00e9 studie, nap\u0159\u00edklad na v\u011bkovou skupinu 56+, adolescenty, na posiluj\u00edc\u00ed d\u00e1vky. V\u00a0p\u0159\u00edprav\u011b je studie zam\u011b\u0159en\u00e1 na vakcinaci d\u011bt\u00ed ve v\u011bku 5\u201312 let. Dal\u0161\u00ed studie budou vyhodnocovat bezpe\u010dnost VLA2001 v roli posiluj\u00edc\u00ed d\u00e1vky po prim\u00e1rn\u00edm o\u010dkov\u00e1n\u00ed jin\u00fdmi typy vakc\u00edn, \u010di jako prim\u00e1rn\u00ed d\u00e1vky po prod\u011bl\u00e1n\u00ed infekce COVID-19, v\u00a0obou p\u0159\u00edpadech s\u00a0odstupem 6 m\u011bs\u00edc\u016f.<\/p>\n

Agentura EMA m\u00e1 k dispozici p\u0159edb\u011b\u017en\u00e9 v\u00fdsledky laboratorn\u00edch test\u016f a data z prvn\u00edch klinick\u00fdch studi\u00ed, kter\u00e1 indikuj\u00ed, \u017ee vakc\u00edna VLA2001 dok\u00e1\u017ee v t\u011ble vytvo\u0159it \u00fa\u010dinn\u00e9 protil\u00e1tky proti SARS-CoV-2. O\u010dek\u00e1v\u00e1 se, \u017ee by mohla b\u00fdt vhodnou o\u010dkovac\u00ed l\u00e1tkou mj. pro odp\u00edra\u010de ned\u00e1vno vyvinut\u00fdch a \u010dasem m\u00e9n\u011b prov\u011b\u0159en\u00fdch mRNA vakc\u00edn.<\/p>\n

MUDr. Monika \u0160imkov\u00e1<\/p>\n

22.2.2022<\/p>\n

Zdroje:<\/p>\n

https:\/\/www.sukl.cz\/sukl\/ema-zahajuje-rolling-review-vakciny-valneva-proti-covid-19<\/a>
\nhttps:\/\/valneva.com\/<\/a>
\nhttps:\/\/cs.wikipedia.org\/wiki\/Vakc%C3%ADna_Valneva_proti_covidu-19<\/a>
\nhttps:\/\/tn.nova.cz\/zpravodajstvi\/clanek\/450359-vakcina-valneva-by-mohla-lakat-i-neockovane-do-cr-se-ale-dostane-zrejme-az-na-jare?campaignsrc=tn_clipboard<\/a>
\nhttps:\/\/cs.wikipedia.org\/wiki\/Vakc%C3%ADna_proti_covidu-19#Inaktivovan%C3%A9_vakc%C3%ADny<\/a>
\nhttps:\/\/covid.gov.cz\/situace\/informace-o-vakcine\/informace-o-dostupnych-vakcinach<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

K\u00a0zaji\u0161t\u011bn\u00ed imunity proti onemocn\u011bn\u00ed COVID-19 se v\u00a0\u010cR aktu\u00e1ln\u011b pou\u017e\u00edv\u00e1 n\u011bkolik vakc\u00edn vyroben\u00fdch r\u016fzn\u00fdmi technologiemi. Dal\u0161\u00ed […]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"image","meta":{"_uag_custom_page_level_css":""},"categories":[1],"tags":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"boldthemes_grid":false,"boldthemes_grid_11":false,"boldthemes_grid_22":false,"boldthemes_grid_21":false,"boldthemes_grid_12":false,"boldthemes_latest_posts":false,"boldthemes_grid_gallery":false},"uagb_author_info":{"display_name":"Jbednar","author_link":"https:\/\/www.mc-praha.cz\/mcp\/author\/jbednar\/"},"uagb_comment_info":0,"uagb_excerpt":"K\u00a0zaji\u0161t\u011bn\u00ed imunity proti onemocn\u011bn\u00ed COVID-19 se v\u00a0\u010cR aktu\u00e1ln\u011b pou\u017e\u00edv\u00e1 n\u011bkolik vakc\u00edn vyroben\u00fdch r\u016fzn\u00fdmi technologiemi. Dal\u0161\u00ed […]","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts\/4192"}],"collection":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/comments?post=4192"}],"version-history":[{"count":1,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts\/4192\/revisions"}],"predecessor-version":[{"id":4194,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts\/4192\/revisions\/4194"}],"wp:attachment":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/media?parent=4192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/categories?post=4192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/tags?post=4192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}